Moderna’s stock falls 4% as CEO says enrollment in vaccine trial has been slowed to ensure diversity

/ / News

Shares of Moderna Inc. were down 4.6% in trading on Friday after the company’s CEO told CNBC that it was slowing down enrollment in the Phase 3 clinical trial for its experimental COVID-19 vaccine to ensure diversity of the study’s participants. The late-stage trial is expected to enroll about 30,000 participants and will be a crucial test to understanding whether the vaccine candidate can protect against infections with the virus. “We believe these efforts will improve the quality of the study and confidence in the vaccine by building evidence for benefit in the communities at highest risk of COVID-19,” a company spokesperson said in an email. As of Aug. 24, the company said that 17,458 people had enrolled in the Phase 3 trial. Moderna’s stock is up 215.6% so far this year, while the S&P 500 has gained 6.9%. |NEW] that it was slowing down enrollment in the Phase 3 clinical trial for its experimental COVID-19 vaccine to ensure diversity of the study’s participants. The late-stage trial is expected to enroll about 30,000 participants and will be a crucial test to understanding whether the vaccine candidate can protect against infections with the virus. “We believe these efforts will improve the quality of the study and confidence in the vaccine by building evidence for benefit in the communities at highest risk of COVID-19,” a company spokesperson said in an email. As of Aug. 24, the company said that 17,458 people had enrolled in the Phase 3 trial. Moderna’s stock is up 215.6% so far this year, while the S&P 500 has gained 6.9%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.